These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24700069)

  • 1. Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years.
    Funahashi Y; Sassa N; Inada-Inoue M; Ando Y; Matsukawa Y; Gotoh M
    Aktuelle Urol; 2014 Mar; 45(2):132-4. PubMed ID: 24700069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aortic dissection during antiangiogenic therapy with sunitinib. A case report.
    Formiga MN; Fanelli MF
    Sao Paulo Med J; 2015; 133(3):275-7. PubMed ID: 25351639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
    Edeline J; Laguerre B; Rolland Y; Patard JJ
    Ann Oncol; 2010 Jan; 21(1):186-7. PubMed ID: 19875754
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
    Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
    Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib as adjuvant therapy for renal cell carcinoma.
    Baker H
    Lancet Oncol; 2016 Nov; 17(11):e485. PubMed ID: 27773485
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib.
    Niwa N; Nishiyama T; Ozu C; Yagi Y; Saito S
    Acta Oncol; 2015 Apr; 54(4):561-2. PubMed ID: 25291078
    [No Abstract]   [Full Text] [Related]  

  • 7. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of pazopanib over sunitinib for renal cell carcinoma.
    Granovetter M
    Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
    [No Abstract]   [Full Text] [Related]  

  • 9. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.
    Porta C; Levy A; Hawkins R; Castellano D; Bellmunt J; Nathan P; McDermott R; Wagstaff J; Donnellan P; McCaffrey J; Vekeman F; Neary MP; Diaz J; Mehmud F; Duh MS
    Cancer Med; 2014 Dec; 3(6):1517-26. PubMed ID: 25045157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.
    Khan KH; Fenton A; Murtagh E; McAleer JJ; Clayton A
    Tumori; 2012; 98(5):139e-142e. PubMed ID: 23235770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
    Chorianopoulos E; Jäger D; Katus HA; Frey N
    Clin Res Cardiol; 2007 Nov; 96(11):829-30. PubMed ID: 17694380
    [No Abstract]   [Full Text] [Related]  

  • 13. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
    Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
    Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
    Ruggeri EM; Cecere FL; Moscetti L; Doni L; Padalino D; Di Costanzo F
    Ann Oncol; 2010 Sep; 21(9):1926-1927. PubMed ID: 20729535
    [No Abstract]   [Full Text] [Related]  

  • 17. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
    Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
    Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
    [No Abstract]   [Full Text] [Related]  

  • 18. Rectal perforation after two years of treatment with sunitinib for metastatic kidney cancer.
    Bladé JS; Bourgouin S; Romeo É; Boudin L; de Jauréguiberry JP
    Presse Med; 2014 Nov; 43(11):1293-5. PubMed ID: 24999082
    [No Abstract]   [Full Text] [Related]  

  • 19. Fatigue with sunitinib-induced hypothyroidism.
    Senior K
    Lancet Oncol; 2007 Feb; 8(2):101. PubMed ID: 17288042
    [No Abstract]   [Full Text] [Related]  

  • 20. Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy.
    Massari F; Ciccarese C; Bimbatti D; Fantinel E; Modena A; Simbolo M; Brunelli M; Artibani W; Martignoni G; Scarpa A; Tortora G
    Anticancer Drugs; 2015 Apr; 26(4):469-73. PubMed ID: 25569703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.